T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
World game at war: why some European nations have threatened a World Cup boycott 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
WALTHAM, Mass., April 24, 2018 -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter financial results on Thursday, May 10, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and provide a company update.
Conference Call Information:
Date: Thursday, May 10, 2018
Time: 8:00 a.m. ET
Domestic Dial-in Number: (866) 323-7965
International Dial-in Number: (346) 406-0961
Conference ID: 6964878
Live webcast: https://edge.media-server.com/m6/p/y98kugt8
A replay of the conference call/webcast will be available from May 10, 2018 at 7:30 p.m. ET until May 17, 2018 at 6:30 p.m. ET. To access the replay, dial (855) 859-2056 for U.S. or (404) 537-3406 for International. The replay conference ID is 6964878.
The live audio webcast of the call can be accessed from the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will also be available for 14 days. The full text of the announcement and financial results will also be available on the Company's website.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant RAD1901 for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact:
Elhan Webb, CFA
Email: [email protected]
Phone: 617-551-4011
